Jaguar Health (JAGX) announced that an access and benefit sharing agreement focused on two cultivated species of the coca plant – Erythroxylum coca and Erythroxylum novogranatense – from Peru has been signed between Peru’s National Institute of Agrarian Innovation and Psilo Scientific, a subsidiary of Filament Health (FLHLF) Corp. The access agreement authorizes the research program of Magdalena Biosciences, a US-based joint venture formed by Jaguar and Filament, into a variety of potential mental health and central nervous system indications for coca.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Animal Health Issues Series M Preferred Stock
- Jaguar Health announces initial proof-of-concept results on crofelemer
- Jaguar Health board authorizes crypto as treasury reserve asset
- Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs
- Jaguar Animal Health Extends Maturity Date for Notes